0
0
12/2/23 at 2:03pm
Organization
Hcplive.com
42 words
0
Comments
Results showed patients treated with vedolizumab experienced less dose escalation and were at a decreased risk of requiring dose escalation compared to patients treated with adalimumab and infliximab.
You are the first to view
https://www.hcplive.com/view/odessa-uc-study-compares-dose-escalation-in-vedolizumab-antitnf--for-ulcerative-colitis
Create an account
or login to join the discussion